Perrigo (PRGO) Other Non Operating Income (2013 - 2026)
Perrigo's (PRGO) quarterly Other Non Operating Income came in at $6.0 million in Q1 2026, up 1400.0% year-on-year from $400000.0 in Q1 2025, and up 561.54% on a QoQ basis from -$1.3 million in Q4 2025.
Perrigo (PRGO) Other Non Operating Income (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Other Non Operating Income data on file, last reported at $6.0 million in Q1 2026.
- On a quarterly basis, Other Non Operating Income rose 1400.0% year-over-year to $6.0 million in Q1 2026; TTM through Mar 2026 was $2.1 million, a 121.88% increase from a year earlier, with the FY2025 full-year figure at -$13.2 million, down 97.01% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $6.0 million, up from -$1.3 million in the prior quarter.
- Over the last five years, Other Non Operating Income for PRGO reached as high as $9.7 million in Q3 2023 and fell as low as -$9.3 million in Q3 2022.
- Historically, Other Non Operating Income has averaged -$913333.3 across 5 years, with a median of -$1.3 million in 2025.
- Across the five-year window, Other Non Operating Income plunged 145.45% in 2023 and surged 1400.0% in 2026, its largest moves.
- Year by year, Other Non Operating Income stood at -$4.4 million in 2022, then sank by 45.45% to -$6.4 million in 2023, then surged by 76.56% to -$1.5 million in 2024, then advanced by 13.33% to -$1.3 million in 2025, then surged by 561.54% to $6.0 million in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were $6.0 million in Q1 2026, -$1.3 million in Q4 2025, and -$2.6 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.04 Bn | 325.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 6.00 Mn |
| Dec 31, 2025 | -1.30 Mn |
| Jun 28, 2025 | -2.60 Mn |
| Mar 29, 2025 | 400,000.00 |
| Dec 31, 2024 | -1.50 Mn |
| Sep 28, 2024 | -5.10 Mn |
| Jun 29, 2024 | -3.40 Mn |
| Mar 30, 2024 | -400,000.00 |
| Dec 31, 2023 | -6.40 Mn |
| Jul 1, 2023 | 9.70 Mn |
| Apr 1, 2023 | -500,000.00 |
| Dec 31, 2022 | -4.40 Mn |
| Oct 1, 2022 | 4.00 Mn |
| Jul 2, 2022 | -9.30 Mn |
| Apr 2, 2022 | 1.10 Mn |
| Dec 31, 2021 | -18.50 Mn |
| Apr 3, 2021 | -2.40 Mn |
| Dec 31, 2020 | 1.60 Mn |
| Sep 26, 2020 | -20.00 Mn |
| Jun 27, 2020 | -17.10 Mn |